ClinicalTrials.gg
RecruitingNCT07535801STRESSDEFISUpdated Apr 23, 2026

Recording Stress Biomarkers in Autism Spectrum Disorders

An observational study in Autism Spectrum Disorder With Intellectual Deficiency, sponsored by Universite Cote d'Azur. Recruiting at 1 site in France. Open to participants aged 3 Years to 22 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by Universite Cote d'Azur · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
3 Years to 22 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 110 studies in Autism Spectrum Disorder with a site in France — 51 open to participants now, 55 under way, 2 of them phase 3. Autism Spectrum Disorder · France.

Planned enrollment
28th of 33
60 · median 120
Started
2026
with 14 others
Observational
33 of 110
17 open now
Primary completion
2027-09
later than 31 of 54 live
Registered
102nd of 110
by date

Among the 110 studies in Autism Spectrum Disorder with a site in France, this one is the 28th largest by planned enrollment of the 33 observational ones that give a count, is one of 15 that started in 2026, is one of 33 observational ones, reaches primary completion later than 31 of the 54 other live ones, and was the 102nd registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

51 of the 110 studies in Autism Spectrum Disorder with a site in France are open now. Recruiting first, the newest first:

45 more — sign in →

All 51 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 3 Years to 22 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Autism Spectrum Disorder with a site in France, or all of them as a file.
02

Study summary

The goal of this observational study is to learn how stress affects children and young people with autism spectrum disorder (ASD). Many individuals with autism experience strong stress reactions that may lead to challenging behaviours such as agitation, withdrawal, aggression, or self-injury. These behaviours can be difficult to predict, especially in people who have limited communication abilities.

Researchers want to better understand how the body reacts to stress in real-life situations. The study focuses on two main biological systems involved in the stress response:

the autonomic nervous system, which produces fast reactions such as changes in heart rate and sweating, and the hypothalamic-pituitary-adrenal axis, which produces slower hormonal responses such as cortisol.

The main questions the study aims to answer are:

  • Do physiological stress signals differ between individuals with ASD and those without ASD?
  • Are there differences in physiological stress responses between individuals with ASD and non-ASD participants?
  • Can physiological markers help identify stress earlier in people with autism?

Researchers will compare children and young people with autism to a control group of participants without autism to see whether their stress responses differ.

Participants will take part in monitoring during their normal daily activities. This allows researchers to observe stress responses in natural environments such as school, home, or specialized care institutions.

Participants will:

  • Wear a wrist device during the day that measures heart rate, heart rate variability, skin conductance, skin temperature, and movement
  • Provide saliva samples in the morning and afternoon to measure stress hormones such as cortisol and alpha-amylase
  • Have additional saliva samples collected after behavioural crises or stressful events when possible
  • Be observed by a trained researcher who records behavioural events and the surrounding context

Researchers will combine physiological data, behavioural observations, and contextual information such as physical activity, environmental conditions, and daily routines. This will help identify patterns of stress in everyday life.

The results of this study may help researchers better understand the physiology of stress in autism and support the future development of wearable systems that could detect stress early and help prevent behavioural crises.

03

Conditions studied

  • Autism Spectrum Disorder With Intellectual Deficiency

Keywords

  • autism spectrum disorder
  • stress biomarkers
  • autonomic nervous system
  • heart rate variability
  • challenging behavior
  • ecological assessment
  • profound autism
  • hypothalamic-pituitary-adrenal axis
  • skin conductance
  • salivary cortisol
  • salivary alpha amylase
04

Who can participate

Ages eligible
3 Years to 22 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of children and adolescents aged 3 to 22 years. Two groups are included: individuals diagnosed with autism spectrum disorder (ASD) presenting recurrent behavioral crises, and a neurotypical control group without neurodevelopmental disorders. Participants with ASD are recruited from specialized medico-social institutions providing care and educational support for individuals with neurodevelopmental conditions. Control participants are recruited from the general population through community outreach and school-based information to families.

Participants are observed during their regular daily activities in naturalistic environments such as specialized institutions, schools, or home settings. Continuous physiological monitoring, behavioral observation, and biological sampling are conducted during daytime institutional sessions.

Eligibility criteria

  1. Autism Spectrum Disorder (ASD) Group Inclusion Criteria

    • Age between 3 and 22 years
    • Clinical diagnosis of autism spectrum disorder according to established diagnostic criteria
    • Presence of recurrent behavioral crises (minimum of three episodes per week)
    • Enrollment in a participating institution or care structure
    • Written provided by a parent or legal guardian
    • Assent from the participant when developmentally appropriate

    Exclusion Criteria:

    • Known cardiac or homonal disorders that may interfere with physiological monitoring
    • Lack of consent from parents or legal guardians
  2. Control Group (Neurotypical Participants) Inclusion Criteria

    • Age between 3 and 22 years
    • No diagnosis of autism spectrum disorder or other neurodevelopmental disorder
    • No history of major psychiatric or neurological disorders
    • Written informed consent provided by a parent or legal guardian
    • Assent from the participant when developmentally appropriate

Exclusion Criteria

  • Known cardiac or hormonal disorders affecting physiological measurements
  • Current diagnosis of neurodevelopmental or psychiatric disorder
  • Lack of parental or guardian consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Autism Spectrum Disorder Participants

    The cohort includes children and adolescents aged 3 to 22 years with a clinical diagnosis of autism spectrum disorder (ASD). Participants are recruited from specialized medico-social institutions providing care and educational support for individuals with neurodevelopmental disorders. To be eligible for inclusion, participants must present frequent challenging behaviours, defined as at least three behavioural crises per week (e.g., agitation, aggression, self-injurious behaviours, or severe emotional dysregulation). Participants must also be able to tolerate the placement of a wearable physiological monitoring device during daytime activities. Participants with known cardiac disorders or hormonal disorders that may affect physiological stress measurements are excluded. Written informed consent is obtained from parent

  • Neurotypical Participants

    The control cohort includes children and adolescents aged 3 to 22 years from the general population. Participants in this group do not have a diagnosis of autism spectrum disorder or other neurodevelopmental disorders. Control participants are recruited through community outreach, schools and information provided to families. They are selected to be comparable to the ASD group in terms of age and sex as closely as possible. Participants with known cardiac disorders or hormonal disorders that may affect physiological stress measurements are excluded. Written informed consent is obtained from parents or legal guardians prior to participation. The control participants follow the same monitoring procedures as the ASD group during their usual daily activities.

06

What researchers measure

Primary outcomes

  1. Autonomic Physiological Stress Markers During Behavioral Stress Episodes

    Continuous autonomic physiological signals are recorded using a wearable device during daytime monitoring. The primary outcome consists of variations in autonomic stress markers including heart rate (HR), heart rate variability (HRV), and electrodermal activity (EDA) in relation to behavioral stress events and crisis episodes recorded during observation. These physiological signals will be analyzed to identify changes associated with stress states and behavioral dysregulation in naturalistic settings.

    Time frame: Continuous monitoring during the 4-day observation period (approximately 8 hours per day).

Secondary outcomes

  1. Salivary Cortisol Concentration

    Salivary cortisol levels are measured as a biomarker of hypothalamic-pituitary-adrenal (HPA) axis activation. Samples are collected twice daily (morning and afternoon) and after behavioral crisis events when feasible. Cortisol concentrations are quantified using enzyme-linked immunosorbent assay (ELISA) techniques.

    Time frame: Collected during the 4-day observation period (morning, afternoon, and post-crisis when applicable).

  2. Salivary Alpha-Amylase Activity

    Salivary alpha-amylase activity is measured as an indicator of sympathetic nervous system activation. Samples are collected using passive saliva swabs and analyzed using a kinetic enzymatic assay.

    Time frame: Collected during the 4-day observation period (morning, afternoon, and post-crisis when applicable).

  3. Frequency and Duration of Behavioral Stress Episodes

    Behavioral stress indicators and crisis episodes are recorded using a structured Antecedent-Behavior-Consequence (ABC) observation grid completed by the investigator during the monitoring period. Outcomes include the frequency and duration of behavioral dysregulation events such as agitation, self-injurious behavior, aggressive behavior, withdrawal, and emotional distress

    Time frame: Recorded continuously during the 4-day observation period.

Other outcomes

  1. Behavioral Problems Inventory (BPI) Scores

    Parents complete the Behavioral Problems Inventory (BPI) questionnaire to assess the frequency and severity of self-injurious, stereotyped, and aggressive behaviors in everyday life. The BPI provides a standardized behavioral profile for each participant.

    Time frame: Assessed at baseline.

  2. Nonverbal Cognitive Functioning

    Nonverbal cognitive ability is assessed using the Leiter International Performance Scale - Third Edition (Leiter-3), a nonverbal intelligence test designed for individuals aged 3 to 75 years and suitable for participants with communication difficulties.

    Time frame: Assessed Day 1.

  3. Adaptive Functioning

    Adaptive functioning is evaluated using the Vineland Adaptive Behavior Scales, which measure communication, daily living skills, socialization, and motor skills through caregiver interview or questionnaire.

    Time frame: Assessed at baseline.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Sep 2027, 18 months after the start.

Of 98 non-industry observational studies under Autism Spectrum Disorder, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 120. This study's planned 18 months is below that.

Counting every sponsor, half of 112 studies reached it within 40 months; a quarter within 26 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Apr 17, 2026
StartActual
Mar 23, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Jan 2028
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07535801
Lead sponsor
Universite Cote d'Azur
Responsible party
Susanne Thümmler (Principal investigor, Universite Cote d'Azur) — Principal investigator
First posted
Apr 17, 2026
Start date
Mar 23, 2026
Primary completion
Sep 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Apr 23, 2026

Study contacts

Susanne THÜMMLER, MDC- HDR -PhD
Contact
Susanne.THUMMLER@univ-cotedazur.fr
+33 4 92 03 03 26

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion